<DOC>
	<DOCNO>NCT00056407</DOCNO>
	<brief_summary>This 4-year study compare safe effective oral investigational medicine ( compare placebo ) preventing development prostate cancer men define study entrance criterion increase risk prostate cancer . Study visit clinic occur every 6 month 4 year ( 10 clinic visit ) , prostate biopsy perform 2 4 year treatment .</brief_summary>
	<brief_title>`` REDUCE '' - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion criterion : Informed consent participate study . Have single negative prostate biopsy within 6 month prior enrollment study . Have PSA ( prostate specific antigen ) 2.5 10 5060 year age ; PSA 3.0 10 age 60 . Ability participate study 4 year . Exclusion criterion : More one previous negative prostate biopsy . History prostate cancer . Previous prostate surgery . Inability urinate require need catheter previous 2 year . Any condition ( benign prostatic hypertrophy ) may result urinary symptom change urine flow rate . Cancer within previous 5 year ( basal squamous cell cancer skin ) . Any unstable serious medical condition . Use within past 12 month finasteride ( Proscar Propecia ) , dutasteride ( Avodart ) , testosterone , drug block action male hormone .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate cancer prevention</keyword>
	<keyword>prostate</keyword>
	<keyword>BPH</keyword>
	<keyword>enlarge prostate</keyword>
	<keyword>PSA</keyword>
	<keyword>prostate cancer</keyword>
</DOC>